The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving disease eradication in patients with lymphoid malignancies not eligible for standard transplantation.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
40
12 g/m2 x 3 days
Chaim Sheba Medical Center
Tel Litwinsky, Tel-Hashomer, Israel
disease-free survival
Time frame: 2 years after transplantation
treatment-related mortality
Time frame: 2 year after transplantation
GVHD
Time frame: 2 year after transplantation
relapse
Time frame: 2 year after transplantation
overall survival
Time frame: 2 year after transplantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.